the GHRH analog that had an FDA-approved life and death
1982 (isolation/sequencing of GHRH); 1990 and 1997 (Sermorelin's two FDA approvals as Geref)
Scientists spent nearly two decades hunting for the hormone that tells the pituitary to release growth hormone — and it finally turned up not in the brain, where it belonged, but leaking out of a tumor in a patient's pancreas.
By the late 1970s, Andrew Schally and Roger Guillemin had shared a Nobel Prize for reeling in the hypothalamus's chemical messengers one by one — yet one prize catch kept slipping the net: growth hormone-releasing hormone (GHRH), the molecule that tells the pituitary to release growth hormone. Everyone knew it had to exist; damage the hypothalamus and GH secretion collapsed. The problem was sheer scarcity — the brain hoards GHRH in such vanishing amounts that isolating the earlier releasing hormones had taken on the order of a million fragments of sheep hypothalami, and GHRH refused to crack under the same brute-force grind.
The breakthrough arrived from the least likely place imaginable: not the brain at all, but a patient's pancreas. In 1981, researchers Frohman and Szabo showed that certain rare pancreatic and carcinoid tumors could churn out GHRH by mistake, saddling their victims with acromegaly — adult-onset gigantism — as a bizarre hormonal side effect. One such patient, carrying a GHRH-spewing pancreatic tumor, came under the care of endocrinologist Michael Thorner at the University of Virginia. The tumor was doing, for free, the very thing decades of brain-tissue purification never could: concentrating the elusive hormone into usable quantities.
What followed in 1982 was a genuine publication race. Guillemin's team at the Salk Institute sequenced a 44-amino-acid version and published it in Science; within months, Jean Rivier, Joachim Spiess, Wylie Vale and Thorner reported a related 40-residue peptide from a second acromegalic patient's tumor in Nature. Researchers soon discovered the full molecule was overkill — its first 29 amino acids did the entire job at the receptor. That trimmed-down, more stable fragment, GHRH(1-29), is Sermorelin.
Sermorelin even had a real FDA career, if a quiet one. It was approved in December 1990 as a diagnostic tool, then in September 1997 as Geref, a treatment for growth failure in children. But it never became a star — recombinant human growth hormone owned the market, and daily injections of a releasing hormone were a harder sell than simply topping up GH directly. Sole manufacturer EMD Serono pulled the plug in 2008, the FDA withdrew the approvals in 2009, and a 2013 Federal Register notice went out of its way to clarify it was killed for commercial reasons — not because anything was ever wrong with it.
Verdict: true. Independent sources — PubMed, Science, Nature, and the Federal Register itself — back the whole arc: a hormone hunted in the brain for two decades, finally isolated from pancreatic-tumor tissue in a 1982 publication race, and later pulled from the market in 2008-09 for purely commercial reasons, not safety. The one soft spot is the "million sheep hypothalami" used to set the scene — that figure varies between sources, so we've hedged it to "on the order of a million."
Since 2009 there has been no branded Sermorelin at all. Every dose in circulation now comes either from <b>503A/503B compounding pharmacies</b> on a physician's prescription or from the unregulated research-chemical market. It has found a busy second life in anti-aging and longevity clinics as a gentler, "let the body make its own GH" alternative to straight recombinant HGH, and its spotless record — discontinued for business, never for safety — keeps it one of the least controversial names in the peptide world. As of 2026, though, tighter FDA compounding-attestation rules have made the off-label anti-aging scripts noticeably harder to obtain than strictly clinical ones.
